

## Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following results was reported at ASCO 2023 from the Phase III SWOG-S1826 study, comparing nivolumab with doxorubicin/vinblastine/dacarbazine (AVD) to brentuximab vedotin (BV) with AVD for advanced-stage classic Hodgkin lymphoma (cHL)?
  - Nivolumab/AVD improved progression-free survival
  - Nivolumab/AVD improved event-free survival
  - Both a and b
  - Neither a nor b
- Which of the following statements best describes the objective response rate (ORR) and complete response (CR) rate observed with early-stage cHL treated with BV, nivolumab, doxorubicin and dacarbazine in part C of the Phase II SGN35-027 trial?
  - ORR and CR rate were moderately low
  - ORR was moderately high but the CR rate was low
  - ORR was extremely high but the CR rate was low
  - ORR and CR rate were moderately high
  - ORR and CR rate were extremely high
- Which of the following Bruton tyrosine kinase (BTK) inhibitors was recently voluntarily withdrawn from the US market for relapsed/refractory (R/R) mantle cell lymphoma and marginal zone lymphoma?
  - Acalabrutinib
  - Ibrutinib
  - Pirtobrutinib
  - Zanubrutinib
- The ongoing Phase III ESCALADE trial is evaluating the addition of acalabrutinib to R-CHOP for patients with which type of diffuse large B-cell lymphoma (DLBCL)?
  - R/R germinal center B-cell-like (GCB)
  - R/R non-germinal center B-cell-like (non-GCB)
  - Untreated GCB
  - Untreated non-GCB
- The ongoing Phase III ARCHED trial is evaluating the addition of which of the following BTK inhibitors to R-mini-CHOP for older patients with previously untreated DLBCL?
  - Acalabrutinib
  - Ibrutinib
  - Pirtobrutinib
  - Zanubrutinib